Consistently with these observations, co-treatment with adagrasib and anti- PD-1 demonstrated complete and prolonged response in vivo, without tumor regrowth after tumor cell inoculation, and increased PFS in KRAS G12C genetically engineered mouse models, compared with single-agent monotherapy (94). The gene discussed is KRAS; the disease is neoplasm.